Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOR NASDAQ:BCDA NASDAQ:BVXV OTCMKTS:ENZN NASDAQ:LIFE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$1.40$1.67$1.00▼$3.20$8.11M0.8301,131 shs48,009 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENZNEnzon Pharmaceuticals$0.07-3.9%$0.08$0.06▼$0.24$5.37M0.3153,033 shs15,479 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCDABioCardia-4.45%-3.79%-1.06%-40.64%-43.75%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-3.59%-0.79%-5.17%-6.35%-28.38%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$1.40$1.67$1.00▼$3.20$8.11M0.8301,131 shs48,009 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENZNEnzon Pharmaceuticals$0.07-3.9%$0.08$0.06▼$0.24$5.37M0.3153,033 shs15,479 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCDABioCardia-4.45%-3.79%-1.06%-40.64%-43.75%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-3.59%-0.79%-5.17%-6.35%-28.38%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/ABCDABioCardia 2.50Moderate Buy$25.001,692.11% UpsideBVXVBiondVax Pharmaceuticals 0.00N/AN/AN/AENZNEnzon Pharmaceuticals 0.00N/AN/AN/ALIFEaTyr Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LIFE, ENZN, BVXV, ACOR, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/23/2025BCDABioCardiaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/22/2025BCDABioCardiaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BCDABioCardia$60K135.08N/AN/A$0.18 per share7.75BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AENZNEnzon Pharmaceuticals$30K178.85$0.01 per share7.44$0.04 per share1.81LIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/ABCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/12/2025 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AENZNEnzon Pharmaceuticals$780K-$0.03N/A∞N/AN/A-91.38%-4.03%11/3/2025 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/ALatest LIFE, ENZN, BVXV, ACOR, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025BCDABioCardia-$0.25N/AN/AN/AN/AN/A8/14/2025Q2 2025ENZNEnzon PharmaceuticalsN/A-$0.02N/A-$0.02N/AN/A8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCDABioCardiaN/A0.330.33BVXVBiondVax PharmaceuticalsN/A4.124.12ENZNEnzon PharmaceuticalsN/A55.7155.71LIFEaTyr Pharma0.026.076.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCDABioCardia20.57%BVXVBiondVax Pharmaceuticals11.83%ENZNEnzon PharmaceuticalsN/ALIFEaTyr Pharma61.72%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCDABioCardia20.00%BVXVBiondVax Pharmaceuticals6.03%ENZNEnzon Pharmaceuticals0.40%LIFEaTyr Pharma3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCDABioCardia405.81 million4.65 millionOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableENZNEnzon PharmaceuticalsN/A74.21 million73.92 millionNot OptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableLIFE, ENZN, BVXV, ACOR, and BCDA HeadlinesRecent News About These CompaniesDolly Varden Silver Closes $34 Million Bought-Deal FinancingOctober 23 at 9:07 AM | newsfilecorp.comNAllied Critical Metals Closes Upsized $16.25 Million LIFE OfferingOctober 21 at 7:06 PM | newsfilecorp.comNAmerican Tungsten Reprices Non-Brokered LIFE Private Placement to $2.58 per ShareOctober 20, 2025 | newsfilecorp.comNPesoRama Announces LIFE Offering and Concurrent Private Placement OfferingOctober 20, 2025 | newsfilecorp.comNUniDoc Announces Amended LIFE OfferingOctober 17, 2025 | accessnewswire.comAEmperor Metals Announces Final Over-Subscribed Closing of LIFE Offering for Aggregate Gross Proceeds of $11 MillionOctober 17, 2025 | newsfilecorp.comNNord Precious Metals Closes Fully Subscribed Non-Brokered LIFE Financing and Concurrent Non-Brokered Private Placement Raising an Aggregate of $4,000,000October 17, 2025 | newsfilecorp.comNAmerican Tungsten Upsizes Non-Brokered LIFE Private Placement to $20 MillionOctober 15, 2025 | newsfilecorp.comNStandard Uranium closes LIFE offeringOctober 15, 2025 | proactiveinvestors.comStandard Uranium Announces Closing of LIFE OfferingOctober 15, 2025 | newsfilecorp.comNFormation Metals Announces Upsize to Previously Announced LIFE Offering and Private Placement of Units to $8.6 MillionOctober 14, 2025 | accessnewswire.comAPan American Closes LIFE Offering and Concurrent Private Placement OfferingOctober 14, 2025 | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYROctober 12, 2025 | markets.businessinsider.comaTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial FailureOctober 10, 2025 | quiverquant.comQGoldcliff Announces Closing of Second and Final Tranche of its "LIFE" OfferingOctober 9, 2025 | accessnewswire.comAMcFarlane Lake Announces Filing of Amended and Restated LIFE Offering DocumentOctober 7, 2025 | newsfilecorp.comNAllied Critical Metals Announces Upsized $16.25 Million LIFE OfferingOctober 7, 2025 | newsfilecorp.comNRETRANSMISSION UniDoc Announces LIFE OfferingOctober 7, 2025 | accessnewswire.comAMidnight Sun Mining increases 'bought deal' LIFE offering to C$17.5MOctober 3, 2025 | proactiveinvestors.comMidnight Sun Announces Upsize to Previously Announced “Bought Deal†LIFE Offering and Private Placement of Units to C$17.5 MillionOctober 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Coca-Cola Stock Dips—Is CELH the Growth Your Portfolio Needs?By Gabriel Osorio-Mazilli | October 10, 2025LIFE, ENZN, BVXV, ACOR, and BCDA Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BioCardia NASDAQ:BCDA$1.40 0.00 (0.00%) Closing price 03:58 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Enzon Pharmaceuticals OTCMKTS:ENZN$0.07 0.00 (-3.86%) As of 09:53 AM EasternEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
